Experimental drug KER-065 aims to slow muscle decline in duchenne muscular dystrophy
Disease control
Not yet recruiting
This phase 2 trial tests an experimental drug called KER-065 in adult and pediatric males with Duchenne Muscular Dystrophy (DMD), a genetic condition that causes progressive muscle weakness. The study includes both those who can walk and those who cannot, and all participants mus…
Phase: PHASE2 • Sponsor: Keros Therapeutics, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC